Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Researchers Use the ProteOn™ XPR36 system to Study the Mechanisms Underlying Cancer, Alzheimer’s Disease, and Other Conditions

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Bio-Rad Laboratories, Inc. announces that the ProteOn Webinar Series will continue in fall 2012.

The webinar series showcases the latest cancer and disease research utilizing the ProteOn XPR36 protein interaction array system, an instrument that uses surface plasmon resonance (SPR) to generate rich, label-free kinetic binding data. Previously presented topics include the use of SPR for the identification and characterization of phosphoinositide signaling lipids that have been linked to cancer and in studies aimed at understanding protein misfolding, aggregation, and tissue deposition associated with neurodegenerative conditions such as Alzheimer’s disease.

“The webinars introduced the latest applications of SPR technology for drug discovery workflows and provided valuable updates on the instrument’s software and hardware,” said Dr Ralf J. Hosse, Antibody Engineering Group Leader at Roche Glycart in Switzerland.

Cancer and Alzheimer’s Disease Applications
In a July 2012 webinar, Dr Lily Sommer of the Paterson Institute for Cancer Research in Manchester, U.K., described the identification and characterization of novel phosphoinositide-binding proteins using the ProteOn XPR36 system. Phosphoinositides are signaling lipids whose misregulation has been linked to cancer. The studies were undertaken using Bio-Rad’s ProteOn liposome capturing kit, which uses DNA hybridization to selectively capture liposomes to detect phosphoinositide-protein interactions.

Marco Gobbi of the Mario Negri Institute in Milan, Italy hosted a webinar session titled “Novel Applications of SPR to Study Amyloidogenic Peptides and Proteins.” He discussed novel SPR screening applications for both mutation analysis and investigating the effects anti-amyloidogenic drug candidates. The results of this work were published in the Journal of Biological Chemistry in June 2012.

An increasing number of diseases are now being associated with misfolding, aggregation, and tissue deposition of specific proteins, such as in Alzheimer’s disease. Soluble oligomers of the amyloid-β (Aβ) peptide play a key role in the pathogenesis of Alzheimer’s disease, but their elusive nature makes detection challenging. Gobbi and his team demonstrated that SPR measurements can be particularly useful for the kinetic analysis of the elongation of amyloid fibrils and the detection of soluble oligomeric species, which cannot be achieved by other techniques.  

Best Practices in SPR
The webinar series kicked off with a session that focused on guidelines developed by Professor Gideon Schreiber of the Weizmann Institute of Science in Israel advising researchers on how to best perform label-free interaction analysis. Dr Schreiber is well known in the label-free field and has hosted and chaired many conferences on this topic.

Drug Discovery and Development Applications
Dr Dalia Shezifi, manager of the Bio-Rad Haifa Applications Team in Israel, focused on label-free analysis of small molecules and peptides binding to liposomes. Her work demonstrated how the ProteOn liposome capturing kits have been used to address important issues in drug development, such as the binding of small molecule drugs to liposomes when estimating the intestinal absorptivity of new drugs.

To conclude the series, Gary Ross, a Bio-Rad field application specialist, described how the ProteOn system was used to perform antibody quantification and full protein kinetic analysis in a single 45-minute experiment. This application is an important advance for researchers involved in antibody screening, as it provides rich data in a single experiment on a single platform, saving bench time.

“The presentations were a good way to inspire new ideas and assays that may be performed in the future,” said Johan Nilvebrant, a PhD student at the KTH Royal Institute of Technology in Sweden.

New Season, New Series
Bio-Rad’s next SPR webinar series will take place this fall, kicking off on Sept. 25 with a presentation by Dr Carlotta Chiappa, a research scientist at the DiaSorin Research Center in Geranzano, Italy, on antibody screening for the development of a diagnostic test for Clostridium difficile. In October, Dr Jonathan Popplewell, a Bio-Rad application scientist, will present a webinar focusing on best practices for SPR data processing and downstream analysis. Dr Lisa Scalfone, a postdoctoral researcher at the Stanford University School of Medicine, will talk about how the ProteOn XPR36 system was used in a novel workflow to develop antibodies against the influenza virus. The last speaker in the fall series, Dr Ladislav Bumba, a postdoctoral researcher at the Institute of Microbiology in Prague, Czech Republic, will discuss the analysis of the interactions of bacterial toxins with target cell molecules in bacterial pathogenesis.

Please visit to register. 

All the webinars from this series can be viewed at

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
The Company has launched new Bio-Plex Pro™ Human Diabetes Assay Panels for its Bio-Plex® suspension array system.
Tuesday, June 24, 2008
Bio-Rad Announces Web Seminar Series
Web seminar series area includes Spectroscopy, Chromatography, ADME/Tox and Metabolomics.
Friday, May 05, 2006
Scientific News
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos